Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry
Background: Guidelines strongly recommend patients with heart failure with reduced
ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical …
ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical …
Titration of medical therapy for heart failure with reduced ejection fraction
Background: Guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …
Comparison of international guidelines for assessment of suspected stable angina: insights from the PROMISE and SCOT-HEART
PD Adamson, DE Newby, CL Hill, A Coles… - JACC: cardiovascular …, 2018 - jacc.org
Objectives: This study sought to compare the performance of major guidelines for the
assessment of stable chest pain including risk-based (American College of …
assessment of stable chest pain including risk-based (American College of …
Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry
M Vaduganathan, GC Fonarow, SJ Greene… - Heart Failure, 2020 - jacc.org
Objectives The purpose of this study was to characterize the clinical profile, treatment
patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart …
patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart …
Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the United States
Background Current guidelines recommend sacubitril/valsartan for patients with heart failure
with reduced ejection fraction, but the rate of adoption in the United States has been slow …
with reduced ejection fraction, but the rate of adoption in the United States has been slow …
Age-related differences in the noninvasive evaluation for possible coronary artery disease: insights from the prospective multicenter imaging study for evaluation of …
A Lowenstern, KP Alexander, CL Hill, B Alhanti… - JAMA …, 2020 - jamanetwork.com
Importance Although cardiovascular (CV) disease represents the leading cause of morbidity
and mortality that increases with age, the best noninvasive test to identify older patients at …
and mortality that increases with age, the best noninvasive test to identify older patients at …
The PROMISE minimal risk score improves risk classification of symptomatic patients with suspected CAD
LD Rasmussen, CB Fordyce, L Nissen, CL Hill Jr… - Cardiovascular …, 2022 - jacc.org
Background Guidelines for evaluating patients with suspected coronary artery disease
(CAD) recommend pretest probability (PTP) estimation but provide no clear …
(CAD) recommend pretest probability (PTP) estimation but provide no clear …
Treatment persistence of renin-angiotensin-aldosterone-system inhibitors over time in heart failure with reduced ejection fraction
M Vaduganathan, GC Fonarow, SJ Greene… - Journal of Cardiac …, 2022 - Elsevier
Background Clinical practice guidelines support sustained use of renin-angiotensin-
aldosterone-system (RAAS) inhibitors over time in heart failure with reduced ejection …
aldosterone-system (RAAS) inhibitors over time in heart failure with reduced ejection …
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker …
Background In patients with heart failure and reduced ejection fraction (HFrEF), angiotensin
converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), or angiotensin …
converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), or angiotensin …
Presenting symptoms in patients undergoing coronary artery disease evaluation: Association with noninvasive test results and clinical outcomes in the PROMISE trial
A Lowenstern, KP Alexander… - … Quality and Outcomes, 2022 - Am Heart Assoc
Background: Patients evaluated for coronary artery disease have a range of symptoms and
underlying risk. The relationships between patient-described symptoms, clinician …
underlying risk. The relationships between patient-described symptoms, clinician …